Origenis GmbH Announces Research Collaboration with U.S. Cancer Center

– Origenis AI Discovery Platform to Identify and Optimize Small
Molecule Preclinical Development Candidates for Glioblastoma –

MARTINSRIED, Germany–(BUSINESS WIRE)–Origenis GmbH, a privately-held German biopharmaceutical company with a
proprietary platform for AI drug discovery and development, today
announced that the company has entered into a collaboration with
Memorial Sloan Kettering Cancer Center (MSK), New York, targeting
glioblastoma (GBM), a rare but fatal brain cancer.

Under the research and collaboration agreement, Origenis will use its
proprietary AI platform for drug discovery and development. With its
intelligent selection and decision making processes, the platform allows
identification of non-obvious connections between targets, chemical
compounds and their specific properties to turn early leads into
promising drugs candidates. The platform features Cippix®, a
unique tool for evolutionary learning with data extracted from patents,
alongside proprietary biology and chemical knowledge, and the alignment
of novel compounds to targets with real-life chemical synthesis routes
using MolMind®.

In this collaboration, Origenis and MSK will work together to identify
and optimize a novel series of small molecules to inhibit GBM, among the
most fatal of cancers. Although GBM are not the most commonly occurring
cancers, they are among the most deadly because of the challenge of
ensuring drug delivery through the blood brain barrier.

We welcome this opportunity to collaborate with Memorial Sloan
Kettering, one of the world’s leading cancer research facilities, to
utilize our proven platform for discovering and synthesizing novel small
molecules that can cross the blood brain barrier,” said Michael
Almstetter, Chief Executive Officer, Origenis. “We look forward to
pairing their cancer expertise with our unique approach to creating
better Preclinical Development Candidates more directly and quickly.”

About Origenis GmbH
Origenis GmbH is a privately-held German
biopharmaceutical company with a proprietary platform for AI drug
discovery and development, resulting in significant IP generation and
strong patent protection. Origenis’ unique approach to small molecule
medicines creates better Preclinical Development Candidates (PDCs)
faster by identifying non-obvious connections between targets, chemical
compounds and the specific properties needed to make them promising
drugs candidates. The platform features Cippix®, a unique
tool for evolutionary learning with data extracted from patents;MolMind®
for optimal decisions and minimal attrition; MOREsystem® for
the alignment of novel compounds to targets with real-life chemical
synthesis routes and BRAINstorm™ for ensuring brain penetration and
ADME-tox feedback. The Origenis platform has been validated by multiple
partners. For more information, visit www.origenis.com.

Contacts

Michael Almstetter, CEO
Tel: +49 (0)89 780 16 760
Email: [email protected]

Dr. Peter Seufer-Wasserthal, CBO
Tel: +49 (0)89 780 16 760
Email:
[email protected]

error: Content is protected !!